Can a lower dose keep leukemia in check? new study aims to find out
NCT ID NCT07383298
First seen Feb 03, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This study looks at whether reducing the dose of the drug olverembatinib can still keep chronic myeloid leukemia (CML) under control in patients who have already responded well to treatment. About 100 adults with CML in chronic or accelerated phase will take a lower dose (20 mg every other day) for at least 12 months. The goal is to see if the cancer stays in remission while possibly reducing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Conditions
Explore the condition pages connected to this study.